Session Title: Central Nervous System Tumors
Session Type: General Poster Session
Date: Sat, Jun 1
Location: S Hall A2
Time: 8:00 AM - 11:45 AM

- **IND.204 - Poster Board: #3A**
  Phase II study of PX-866 in recurrent glioblastoma. (Abstract #2053)
  Marshall W. Pitz, MD FRCPC

Session Title: Lung Cancer - Non-small Cell Metastatic
Session Type: General Poster Session
Date: Sat, Jun 1
Location: S Hall A2
Time: 8:00 AM - 11:45 AM

- **BR.24 - Poster Board: #33D**
  Exploratory analysis of angiotensin converting enzyme (ACE) and aldosterone (Ald) serum levels as prognostic and predictive biomarkers on the NCIC CTG BR24 trial. (Abstract #8048)
  Jair Bar, MD, PhD

Session Title: Breast Cancer - HER2/ER
Session Type: Poster Discussion Session
Date: Sat, Jun 1
Location: E450b
Time: 8:00 AM - 12:00 PM
Chair and/or Co-Chairs: Stephen R. Johnston, MA, MD, PhD, and Tufia C. Haddad, MD

- **IND.198 - Poster Board: #6**
  A phase Ib study of an anti-HER2 inhibitor, lapatinib, in combination with a c-MET and VEGFR inhibitor, foretinib, in HER2-positive metastatic breast cancer (MBC): Results from NCIC CTG IND.198. (Abstract #518)
  Stephen K. Chia, MD
**Session Title:** Breast Cancer - HER2/ER  
**Session Type:** General Poster Session  
**Date:** Sat, Jun 1  
**Location:** S Hall A2  
**Time:** 1:15 PM - 5:00 PM

- **MA.27 - Poster Board: #4C**  
  Competing risks of death in NCIC CTG MA.27 adjuvant exemestane versus anastrozole.  
  (Abstract #564)  
  Judy-Anne W. Chapman, PhD

---

**Session Title:** Lung Cancer - Non-small Cell Local-regional/Small Cell/Other Thoracic Cancers  
**Session Type:** Poster Discussion Session  
**Date:** Sat, Jun 1  
**Location:** E450b  
**Time:** 1:15 PM - 5:15 PM  
**Chair and/or Co-Chairs:** Christine L. Hann, MD, PhD, and Roy H. Decker, MD, PhD

- **IND.198 - Poster Board: #4**  
  Multittrial evaluation of progression-free survival (PFS) as a surrogate endpoint for overall survival (OS) in previously untreated extensive-stage small cell lung cancer (ES-SCLC): An Alliance-led analysis. (Abstract #7510)  
  Nathan R. Foster, MS

---

**Session Title:** Gynecologic Cancer  
**Session Type:** Oral Abstract Session  
**Date:** Sat, Jun 1  
**Location:** E354b  
**Time:** 3:00 PM - 6:00 PM  
**Chair and/or Co-Chairs:** Paul Haluska, MD, PhD, and Gini F. Fleming, MD

- **OV.16 - 3:30 PM - 3:45 PM**  
  Final results of OV16, a phase III randomized study of sequential cisplatin-topotecan and carboplatin-paclitaxel (CP) versus CP in first-line chemotherapy for advanced epithelial ovarian cancer (EOC): A GCIG study of NCIC CTG, EORTC-GCG, and GEICO.  
  (Abstract #5502)  
  Andres Cervantes-Ruiperez, MD
Session Title: Central Nervous System Tumors  
Session Type: Oral Abstract Session  
Date: Sat, Jun 1  
Location: E253  
Time: 3:00 PM - 6:00 PM  
Chair and/or Co-Chairs: Howard A. Fine, MD, and Mark R. Gilbert, MD

- **CE.5 - 5:15 PM - 5:30 PM**  
  Temozolomide chemotherapy versus radiotherapy in molecularly characterized (1p loss) low-grade glioma: A randomized phase III intergroup study by the EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC 22033-26033). (Abstract #2007)  
  Brigitta G. Baumert, MD, PhD, MBA

---

**Sunday, June 2**

Session Title: Patient and Survivor Care  
Session Type: Oral Abstract Session  
Date: Sun, Jun 2  
Location: S100a  
Time: 8:00 AM - 11:00 AM  
Chair and/or Co-Chairs: Tara O. Henderson, MD, MPH

- **SC.20 - 8:30 AM - 8:45 AM**  
  A randomized trial of single versus multiple fractions (Fx) for re-irradiation (RE-RT) of painful bone metastases (PBM): NCIC CTG SC.20. (Abstract #9502)  
  Edward Chow, MBBS PhD

---

Session Title: Gastrointestinal (Colorectal) Cancer  
Session Type: General Poster Session  
Date: Sun, Jun 2  
Location: S Hall A2  
Time: 8:00 AM - 11:45 AM

- **CO.21 - Poster Board: #15A**  
  A phase III study of the impact of a physical activity program on disease-free survival in patients with high-risk stage II or stage III colon cancer: A randomized controlled trial (NCIC CTG CO.21). (Abstract #TPS3647)  
  Christopher M. Booth, MD
**Session Title:** Gastrointestinal (Noncolorectal) Cancer  
**Session Type:** General Poster Session  
**Date:** Sun, Jun 2  
**Location:** S Hall A2  
**Time:** 8:00 AM - 11:45 AM

- **PA.3 - Poster Board: #18G**  
  Assessment of the association of the VeriStrat test with outcomes in patients (pts) with advanced pancreatic cancer (PC) treated with gemcitabine (G) with or without erlotinib (E) in the NCIC CTG PA.3 phase III trial. (Abstract #4061)  
  Daniel J. Renouf, MD

- **PA.3 - Poster Board: #17G**  
  Significance of baseline quality of life scores in predicting clinical outcomes in an international phase III trial of advanced pancreatic cancer: NCIC CTG PA.3. (Abstract #4053)  
  Michael M. Vickers, MD, FRCPC

---

**Monday, June 3**

**Session Title:** Genitourinary (Prostate) Cancer  
**Session Type:** General Poster Session  
**Date:** Mon, Jun 3  
**Location:** S Hall A2  
**Time:** 8:00 AM - 11:45 AM

- **IND.205 - Poster Board: #36A**  
  NCIC CTG, IND-205: A phase II study of PX-866 in patients with recurrent or metastatic castration resistant prostate cancer (CRPC). (Abstract #5042)  
  Sebastien J. Hotte, MD, MSc

---

**Session Title:** Melanoma/Skin Cancers  
**Session Type:** Poster Discussion Session  
**Date:** Mon, Jun 3  
**Location:** S405  
**Time:** 8:00 AM - 12:00 PM  
**Chair and/or Co-Chairs:** Kevin Kim, MD, and Ryan J. Sullivan, MD

- **IND.202 - Poster Board: #20**  
  Final efficacy results of NCIC CTG IND.202: A randomized phase II study of recombinant interleukin-21 (rIL21) in patients with recurrent or metastatic melanoma (MM). (Abstract #9032)  
  Teresa M. Petrella, MD
**Session Title:** Breast Cancer - Triple-Negative/Cytotoxics/Local Therapy  
**Session Type:** Oral Abstract Session  
**Date:** Mon, Jun 3  
**Location:** N Hall B1  
**Time:** 9:45 AM - 12:45 PM  
**Chair and/or Co-Chairs:** Deborah Toppmeyer, MD, and Eleanor E. Harris, MD

- **MAC.11 - 12:15 PM - 12:30 PM**  
  S0221: Comparison of two schedules of paclitaxel as adjuvant therapy for breast cancer. (Abstract #CRA1008)  
  G. T. Budd, MD

---

**Session Title:** Health Services Research  
**Session Type:** General Poster Session  
**Date:** Mon, Jun 3  
**Location:** S Hall A2  
**Time:** 1:15 PM - 5:00 PM

- **MAP.3 - Poster Board: #13E**  
  NCIC CTG MAP.3: Symptoms and quality of life (QoL) among racial/ethnic minority women taking the aromatase inhibitor (AI) exemestane (EXE) for breast cancer risk reduction. (Abstract #6557)  
  Beverly Moy, MD

---

**Session Title:** Breast Cancer - Triple-Negative/Cytotoxics/Local Therapy  
**Session Type:** Poster Discussion Session  
**Date:** Mon, Jun 3  
**Location:** S102  
**Time:** 1:15 PM - 5:15 PM  
**Chair and/or Co-Chairs:** Melinda L. Telli, MD, and Janice M. Walshe, MD

- **MA.32 - Poster Board: #25**  
  Effect of metformin versus placebo on weight and metabolic factors in initial patients enrolled onto NCIC CTG MA.32, a multicenter adjuvant randomized controlled trial in early-stage breast cancer (BC). (Abstract #1033)  
  Pamela J. Goodwin, MD, MSc
**CO.17 - Poster Board: #20**
Location of colon cancer (right-sided [RC] versus left-sided [LC]) as a predictor of benefit from cetuximab (CET): NCIC CTG CO.17. (Abstract #3528)
Stephanie Y. Brule, MD